| |  Online-Ressource |
|---|
| Verfasst von: | Pfeifer, Heike [VerfasserIn]  |
|---|
| | Wassmann, B. [VerfasserIn] |
|---|
| | Bethge, W. [VerfasserIn] |
|---|
| | Dengler, Jolanta [VerfasserIn] |
|---|
| | Bornhäuser, M. [VerfasserIn] |
|---|
| | Stadler, M. [VerfasserIn] |
|---|
| | Beelen, D. [VerfasserIn] |
|---|
| | Vucinic, V. [VerfasserIn] |
|---|
| | Burmeister, T. [VerfasserIn] |
|---|
| | Stelljes, M. [VerfasserIn] |
|---|
| | Faul, C. [VerfasserIn] |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| | Kiani, A. [VerfasserIn] |
|---|
| | Schäfer-Eckart, K. [VerfasserIn] |
|---|
| | Schwerdtfeger, R. [VerfasserIn] |
|---|
| | Lange, E. [VerfasserIn] |
|---|
| | Kubuschok, B. [VerfasserIn] |
|---|
| | Horst, H. A. [VerfasserIn] |
|---|
| | Gramatzki, M. [VerfasserIn] |
|---|
| | Brück, P. [VerfasserIn] |
|---|
| | Serve, H. [VerfasserIn] |
|---|
| | Hoelzer, D. [VerfasserIn] |
|---|
| | Gökbuget, N. [VerfasserIn] |
|---|
| | Ottmann, O. G. [VerfasserIn] |
|---|
| Titel: | Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia |
|---|
| Verf.angabe: | H. Pfeifer, B. Wassmann, W. Bethge, J. Dengler, M. Bornhäuser, M. Stadler, D. Beelen, V. Vucinic, T. Burmeister, M. Stelljes, C. Faul, P. Dreger, A. Kiani, K. Schäfer-Eckart, R. Schwerdtfeger, E. Lange, B. Kubuschok, H.A. Horst, M. Gramatzki, P. Brück, H. Serve, D. Hoelzer, N. Gökbuget and O.G. Ottmann |
|---|
| E-Jahr: | 2013 |
|---|
| Jahr: | 30 April 2013 |
|---|
| Umfang: | 9 S. |
|---|
| Fussnoten: | Gesehen am 20.01.2022 |
|---|
| Titel Quelle: | Enthalten in: Leukemia |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2013 |
|---|
| Band/Heft Quelle: | 27(2013), 6, Seite 1254-1262 |
|---|
| ISSN Quelle: | 1476-5551 |
|---|
| Abstract: | Minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) for Ph+ acute lymphoblastic leukemia (ALL) is predictive of relapse. Imatinib administration subsequent to SCT may prevent relapse, but the role of scheduling and its impact on outcome are not known. In a prospective, randomized multicenter trial, we compared the tolerability and efficacy of post-transplant imatinib administered either prophylactically (arm A; n=26) or following detection of MRD (arm B; n=29). Prophylactic imatinib significantly reduced the incidence of molecular recurrence after SCT compared with MRD-triggered imatinib (40% vs 69%; P=0.046). Median duration of PCR negativity was 26.5 and 6.8 months, respectively (P=0.065). Five-year survival in both interventional groups was high (80 and 74.5%), despite premature discontinuation of imatinib in the majority of patients because of poor tolerability. Relapse probability was significantly higher in patients who became MRD positive (P=0.017). In conclusion, post-transplant imatinib results in a low relapse rate, durable remissions and excellent long-term outcome in patients with BCR-ABL1-positive ALL irrespective of whether it is given prophylactically or MRD-triggered. Reappearance of BCR-ABL1 transcripts early after SCT or at higher levels identifies a small subset of patients who do not benefit sufficiently from imatinib, and in whom alternative approaches should be explored. |
|---|
| DOI: | doi:10.1038/leu.2012.352 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1038/leu.2012.352 |
|---|
| | Volltext: https://www.nature.com/articles/leu2012352 |
|---|
| | DOI: https://doi.org/10.1038/leu.2012.352 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Acute lymphocytic leukaemia |
|---|
| | Cell transplantation |
|---|
| | Immunosuppression |
|---|
| | Outcomes research |
|---|
| K10plus-PPN: | 1786577275 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia / Pfeifer, Heike [VerfasserIn]; 30 April 2013 (Online-Ressource)
